| ATTR amyloidosis: Genetics and Basic Science Chairs: Merrill D. Benson, Indianapolis, IN, USA Laura Obici, Pavia, Italy Molecular mechanisms of ATTR amyloidosis Maria João Saraiva, Porto, Portugal Driving forces in ATTR amyloidosis Vittorio Bellotti, London, UK and Pavia, Italy Genetic signatures associated with hereditary ATTR amyloidosis Joel Buxbaum, La Jolla, CA, USA Factors involved in increased susceptibility to TTR amyloidogenesis Teresa Coelho, Porto, Portugal |
|
| 14:40 - 15:00 | Discussion |
| Chairs: Mitsuharu Ueda, Kumamoto, Japan Tomás Ripoll-Vera, Palma de Mallorca, Spain |
|
| BASIC SCIENCE I | |
| OP01 | High resolution cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary val30met ATTR amyloidosis Matthias Schmidt, Ulm, Germany |
| OP02 | Defining the cardiac amyloid proteome and its association with patient clinical characteristics and outcomes Taxiarchis Kourelis, Rochester, MN, USA |
| OP03 | Immunogenetic profile of purified pathological plasma cells of patients with light chain amyloidosis Isabel Cuenca, Madrid, Spain |
| OP04 | From protein-protein interaction to protein co-expression networks: a systems biology-based perspective to investigate amyloidosis diseases Dario Di Silvestre, Milano, Italy |
| OP05 | Targeting deubiquitylating enzymes USP14 and UCHL5 in systemic immunoglobulin light chain (AL) amyloidosis Mario Nuvolone, Pavia, Italy |
| OP06 | Membrane and soluble b-cell maturation antigen (BCMA) in systemic light-chain amyloidosis Ping Zhou, Boston, MA, USA |
| 15:52 - 16:10 | Discussion |
| Wild-type Transthyretin Amyloidosis – An epidemic hiding in plain sight Chairs: Pablo García-Pavía, Madrid, Spain When the bright side of TTR breaks the heart Maria João Saraiva, Porto, Portugal Diagnosis and management of wild type TTR amyloidosis Julian Gillmore, London, UK Where the Wild-Type Ones Are Esther González-López, Madrid, Spain |
| Organ Transplantation in Systemic Amyloidosis Chairs: Claudio Rapezzi, Bologna, Italy Pablo García-Pavía, Madrid, Spain Heart transplantation in AL amyloidosis Arnt V. Kristen, Heidelberg, Germany Heart transplantation in ATTR amyloidosis Mathew Maurer, NY, USA Liver transplantation in hereditary ATTR amyloidosis Julie Heimbach, Rochester, USA Kidney transplant in AL amyloidosis and monoclonal immunoglobulin deposition disease: who and when? Nelson Leung, Rochester, MN, USA |
|
| 18:40 - 19:00 | Discussion |
| Experts’ Discussion on ASCT in AL amyloidosis: burning questions Chair: Efstathios Kastritis, Athens, Greece Panelists: Vaishali Sanchorawala, Boston, MA, USA Heather Landau, New York, NY, USA Hasib Sidiqi, Rochester, MN, USA Carlos Fernández de Larrea, Barcelona, Spain Eli Muchtar, Rochester, MN, USA Topics: • Patient selection • Decreasing transplant-related mortality • Pretransplant induction • ASCT in patients with renal function impairment • Any role for consolidation or maintenance? • Is it time for CAR-T cell therapy in AL amyloidosis? |